Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioRestorative Therapies Inc | BRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.27 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.20 - 7.13 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.27 | USD |
BioRestorative Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.93M | 4.71M | - | 146k | -14.42M | -3.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioRestorative Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.30 | 1.45 | 1.25 | 1.38 | 129,109 | -0.03 | -2.31% |
1 Month | 1.38 | 1.65 | 1.21 | 1.32 | 627,429 | -0.11 | -7.97% |
3 Months | 1.76 | 3.6699 | 1.20 | 2.37 | 706,590 | -0.49 | -27.84% |
6 Months | 1.90 | 3.6699 | 1.20 | 2.36 | 336,354 | -0.63 | -33.16% |
1 Year | 3.88 | 7.13 | 1.20 | 2.52 | 195,826 | -2.61 | -67.27% |
3 Years | 8.90 | 8.90 | 1.20 | 3.56 | 197,058 | -7.63 | -85.73% |
5 Years | 8.90 | 8.90 | 1.20 | 3.56 | 197,058 | -7.63 | -85.73% |
BioRestorative Therapies Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |